Joe Wiley

Rare disease specialist says integration with newly acquired Aegerion completed ahead of time

Company said the impact of Covid-19 on its business has been minimised so far

Dublin-based biopharma company has cash position of $60.9m

Firm acquired US-based Aegerion Pharmaceuticals earlier this year

Group plots dual Nasdaq listing to create enlarged rare disease company

Lojuxta revenues driven by UK, France reimbursement approval

Elaine Sullivan leads cancer research firm to an EY Entrepreneur of the Year Award

Amyrt’s EB development asset progressing through phase three clinical trial

Approval for treatment for rare genetic condition paves way for clinical trials in US

FDA move means Irish company could receive voucher ultimately worth up to €300m

Drug treats rare condition which can lead to early blocking of arteries and heart attacks

EY Entrepreneur of the Year finalist Dr Joe Wiley of Amryt Pharma

Firms estimates new deal will increase number of patients for treatment by 25%

Finalists employ more than 2,700 people and generate annual revenues of €150m

Biopharma firm signs new deal for gene therapy that could treat genetic condition EB

Company has further expanded its market coverage for Lojuxta

Latest deal is fourth in three months for Ierish biopharmaceutical company

Derval O’Carroll has more than 25 years experience in pharmaceutical industry

Lojuxta deal is ‘key step’ in growing company’s business for drug in EMEA region

Placing is conditional on shareholder approval at a general meeting on October 9th

Company starts phase III trial for ‘butterfly skin’ disease

Company formed last year through reverse takeover of former oil and gas firm Fastnet